Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ixabepilone

FDA-approved product (injectable, intravenous), marketed as Ixempra Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ixabepilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cytotoxic antibiotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ixabepilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ixabepilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

    NCT04796324 · start 2021-03-01

    Registered record
    Registry ID
    NCT04796324
    Conditions
    Metastatic Breast Cancer
    Interventions
    Ixabepilone Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-03-01
    Completion
    2025-11-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionIxabepilone Injection
    PhasePhase 2
    Registry statusTerminated

  • Breast Cancer Treatment Based on Organ-like Culture

    NCT03925233 · start 2019-01-02

    Registered record
    Registry ID
    NCT03925233
    Conditions
    Breast Cancer Organoids
    Interventions
    Trastuzumab; Doxorubicin Hydrochloride; Epirubicin hydrochloride; Fluorouracil; Paclitaxel; Gemcitabine; Cisplatin; Recombinant Human Endostatin; Pirarubicin hydrochloride; Pyrrolidine; Ixabepilone; Tamoxifen citrate; Vinorelbine tartrate; Carboplatin; Methotrexate; Eribulin mesylate; Toremifene citrate; Anastrozole; Letrozole; Exemestane; Fulvestrant; Olaparib; Bevacizumab; Apatinib mesylate; Pattozumab; Capecitabine; Ear particles; Aidi Injection; Cyclophosphamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-01-02
    Completion
    2021-12-15
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Organoids
    InterventionTrastuzumab; Doxorubicin Hydrochloride; Epirubicin hydrochloride; Fluorouracil +25 more
    PhaseNot recorded
    Registry statusUnknown

  • Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

    NCT03393741 · start 2018-01-29

    Registered record
    Registry ID
    NCT03393741
    Conditions
    Breast Cancer; Breast Neoplasms
    Interventions
    Taxane; Vinorelbine; Ixabepilone; Eribulin; Chemotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-01-29
    Completion
    2024-02-11
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Neoplasms
    InterventionTaxane; Vinorelbine; Ixabepilone; Eribulin +1 more
    PhaseNot recorded
    Registry statusTerminated

  • A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    NCT02915744 · start 2016-11

    Registered record
    Registry ID
    NCT02915744
    Conditions
    Metastasis; Breast Cancer
    Interventions
    NKTR-102; Eribulin; Ixabepilone; Vinorelbine; Gemcitabine; Paclitaxel; Docetaxel; Nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-11
    Completion
    2020-07
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastasis; Breast Cancer
    InterventionNKTR-102; Eribulin; Ixabepilone; Vinorelbine +4 more
    PhasePhase 3
    Registry statusCompleted

  • Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

    NCT01349088 · start 2013-12

    Registered record
    Registry ID
    NCT01349088
    Conditions
    Breast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
    Interventions
    Ixabepilone; Capecitabine; Motesanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2013-12
    Completion
    2018-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Metastatic Breast Cancer; Stage IV Breast Cancer
    InterventionIxabepilone; Capecitabine; Motesanib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

    NCT01446016 · start 2011-09

    Registered record
    Registry ID
    NCT01446016
    Conditions
    Breast Neoplasms; Breast Cancer
    Interventions
    Paclitaxel; Docetaxel; Abraxane; Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2019-03-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Breast Cancer
    InterventionPaclitaxel; Docetaxel; Abraxane; Ixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    NCT01375829 · start 2011-06-27

    Registered record
    Registry ID
    NCT01375829
    Conditions
    Adult Solid Neoplasm
    Interventions
    Ixabepilone; Pharmacological Study; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2011-06-27
    Completion
    2027-03-19
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Solid Neoplasm
    InterventionIxabepilone; Pharmacological Study; Temsirolimus
    PhasePhase 1
    Registry statusActive not recruiting

  • Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

    NCT01220609 · start 2010-11

    Registered record
    Registry ID
    NCT01220609
    Conditions
    Recurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
    Interventions
    Ixabepilone; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-11
    Completion
    2016-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Uterine Corpus Sarcoma; Uterine Corpus Leiomyosarcoma
    InterventionIxabepilone; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

    NCT01168232 · start 2010-09-07

    Registered record
    Registry ID
    NCT01168232
    Conditions
    Recurrent Uterine Corpus Sarcoma; Uterine Carcinosarcoma
    Interventions
    Ixabepilone; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09-07
    Completion
    2013-11-26
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Uterine Corpus Sarcoma; Uterine Carcinosarcoma
    InterventionIxabepilone; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

    NCT01079793 · start 2010-05-26

    Registered record
    Registry ID
    NCT01079793
    Conditions
    Prostate Cancer
    Interventions
    ixabepilone; adjuvant therapy; intensity-modulated radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2010-05-26
    Completion
    2011-10-17
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionixabepilone; adjuvant therapy; intensity-modulated radiation therapy
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

    NCT01084057 · start 2010-05-17

    Registered record
    Registry ID
    NCT01084057
    Conditions
    Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventions
    vorinostat; ixabepilone; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-05-17
    Completion
    2019-09-27
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
    Interventionvorinostat; ixabepilone; laboratory biomarker analysis; pharmacological study
    PhasePhase 1
    Registry statusCompleted

  • Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    NCT01057212 · start 2010-02

    Registered record
    Registry ID
    NCT01057212
    Conditions
    Non-squamous Non-small Cell Lung Cancer
    Interventions
    ixabepilone; bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2013-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Non-small Cell Lung Cancer
    Interventionixabepilone; bevacizumab
    PhasePhase 2
    Registry statusTerminated

  • Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

    NCT01012362 · start 2009-12

    Registered record
    Registry ID
    NCT01012362
    Conditions
    Breast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer; Head and Neck Cancer; Kidney Cancer; Sarcoma; Hepatocellular Cancer
    Interventions
    Pazopanib; Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-12
    Completion
    2013-02
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Lung Cancer; Colon Cancer; Pancreatic Cancer +4 more
    InterventionPazopanib; Ixabepilone
    PhasePhase 1
    Registry statusTerminated

  • Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

    NCT00977574 · start 2009-09-14

    Registered record
    Registry ID
    NCT00977574
    Conditions
    Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Recurrent Malignant Uterine Corpus Neoplasm; Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage; Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
    Interventions
    Bevacizumab; Carboplatin; Ixabepilone; Laboratory Biomarker Analysis; Paclitaxel; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2009-09-14
    Completion
    2027-03-06
    Enrolment
    349

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma +6 more
    InterventionBevacizumab; Carboplatin; Ixabepilone; Laboratory Biomarker Analysis +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

    NCT00798252 · start 2009-03

    Registered record
    Registry ID
    NCT00798252
    Conditions
    Advanced Cancer
    Interventions
    Capecitabine; Doxorubicin; Ixabepilone; Docetaxel; Paclitaxel; Brivanib alaninate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2015-05
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionCapecitabine; Doxorubicin; Ixabepilone; Docetaxel +2 more
    PhasePhase 1
    Registry statusCompleted